AVEG 002

A Phase I Multicenter, Randomized, Double-blind, Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) November 29, 1988
HIVAC-1e,gp160 MN/LAI Vaccinia Env gp160 B; Protein Env gp160 B MN/LAI
HIVAC-1e Viral Vector - Pox
gp160 MN/LAI Protein
USA 54